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Abstract P2X7Rs are distributed throughout all layers of the
retina, and thus, their localisation on various cell types puts
into question their specific site(s) of action. Using a dark-
adapted, ex vivo mouse retinal whole mount preparation, the
present study aimed to characterise the effect of P2X7R acti-
vation on light-evoked, excitatory RGC ON-field excitatory
post-synaptic potentials (fEPSPs) and on outer retinal electro-
retinogram (ERG) responses under comparable conditions.
The pharmacologically isolated NMDA receptor-mediated
RGC ON-fEPSP was reduced in the presence of BzATP, an
effect which was significantly attenuated by A438079 and
other selective P2X7R antagonists A804598 or AF27139. In
physiological Krebs medium, BzATP induced a significant
potentiation of the ERG a-wave, with a concomitant reduction
in the b-wave and the power of the oscillatory potentials.
Conversely, in the pharmacologically modifiedMg2+-free per-
fusate, BzATP reduced both the a-wave and b-wave. The ef-
fects of BzATP on the ERG components were suppressed by
A438079. A role for P2X7R function in visual processing in
both the inner and outer retina under physiological conditions
remains controversial. The ON-fEPSP was significantly re-
duced in the presence of A804598 but not by A438079 or
AF27139. Furthermore, A438079 did not have any effect on
the ERG components in physiological Krebs but potentiated
and reduced the a-wave and b-wave, respectively, when applied
to the pharmacologically modified medium. Therefore, activa-
tion of P2X7Rs affects the function in the retinal ON pathway.
The presence of a high concentration of extracellular ATPwould
most likely contribute to themodulation of visual transmission in
the retina in the pathophysiological microenvironment.
Keywords P2X7 receptor . Adenosine 5′-triphosphate .
Retina . Neuromodulation
Introduction
The P2X7 receptor (P2X7R) is the most diverse receptor sub-
type of the P2X family in both structure and function [1].
ATP-gated P2X7Rs have been detected in neurons and glia,
in both inner and outer synapse-rich and nuclear layers of the
retina. They are functionally expressed by retinal ganglion
cells [2–10] and Müller glial cells [11], and their presence on
amacrine, horizontal [7, 12, 13] and microglial cells [4, 7] has
also been suggested. The upregulation of P2X7R expression
and activation by extracellular ATP is associated with the el-
evation of intracellular calcium and subsequent photoreceptor
and retinal ganglion cell (RGC) death, thus implicating a role
for P2X7Rs in retinal degenerations such as retinitis
pigmentosa, glaucoma, age-related macular degeneration
(AMD) and retinopathies [14, 15].
The P2X7R is relatively insensitive to its extracellular ag-
onist, adenosine 5′-triphosphate (ATP), and exhibits a biphasic
agonist-evoked response, dependent upon the agonist expo-
sure time [16]. Similar to other P2X subtypes, a brief agonist
application induces a reversible, transient inward current
through a non-selective ion channel, permeable to small cat-
ions. Repeated or prolonged agonist application gives rise to a
sustained current, which could ultimately lead to cell death,
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assumed to be associated with the opening of a large pore that
is permeable to molecules of high molecular weight
(<900 Da) [16, 17].
Although P2X7R function in retinal pathophysiology is
becoming established, the role of these receptors in synaptic
function in the healthy retina has remained largely unex-
plored, until now. The specific localisation of P2X7Rs on neu-
rons of the vertical rod-mediated pathway suggests that these
receptors may have an important role in modulating scotopic
visual responses under physiological conditions [7, 13].
Under physiological conditions, in vivo electroretinogram
(ERG) studies have shown alterations to both outer and inner
retinal function, in response to short-term administration of
the P2XR agonist, BzATP, in the rat retina [7, 12, 13].
However, the specific contribution of P2X7Rs to the BzATP-
mediated modulation of retinal function remains elusive. A
further complexity is that P2X7Rs are distributed throughout
all layers of the retina, adding to the uncertainty of the specific
site(s) of action for these receptors in modulating neurotrans-
mission within the retina. In line with this notion, it is unclear
from the sole use of ERG recordings whether P2X7Rs also
directly modulate retinal ganglion cell synaptic function.
A large body of evidence suggests a role for neuronal
P2X7Rs in the modulation of neurotransmitter release and
subsequent regulation of synaptic function [17]. P2X7R-me-
diated neurotransmitter release has been detected in the cere-
bellum [18], cerebral cortex and midbrain preparations
[19–21], hippocampus [22] and neuromuscular junction
[23]. Indeed, similar mechanisms may be at play within the
retina, and the expression of P2X7Rs on Müller glia and mi-
croglia also implicates a contribution to neuromodulation by
non-neuronal sources to visual processing, by the activation of
these receptors.
The aim of the present study was to investigate the effect of
P2X7R activation on visually evoked synaptic responses at the
level of the photoreceptor, the ON bipolar cell, and RGC. We
have performed this using a dark-adapted ex vivo mouse ret-
inal whole mount preparation to record extracellular, light-
evoked retinal responses and with the use of selective
P2X7R compounds. Our findings suggest that functional
P2X7Rs are present throughout the visual pathway in the ret-
ina and that their activation leads to modulation of visual
responses.
Materials and methods
Animals
Adult (4–12 weeks) C57BL/6 mice (Harlan Laboratories,
UK) were housed on a 12-h light/dark cycle, in the
Biological Resources Unit, Institute of Ophthalmology,
University College London. The animals were given
unlimited access to food and water. All procedures were in
accordance with the UK Animals (Scientific Procedures) Act
1986 and approved by the UK Home Office and the
University College London local ethics committee.
Preparation of the ex vivo mouse retinal whole mount
All procedures were carried out in low-light conditions and
red light was used for illumination, unless otherwise stated.
Animals were killed by cervical dislocation and decapitation.
The eyes were rapidly removed and placed into an ice-cold,
oxygenated sucrose Krebs medium containing the following
(mM): sucrose 202, KCl 2, KH2PO4 1.25, MgSO4 10, CaCl2
0.5, NaHCO3 26 and glucose 10. The eyes were placed in a
Petri dish containing sucrose Krebs medium, under a dissec-
tion microscope, and the optic nerve and extra-ocular muscle
tissue were removed from the sclera. A cut was made at the
ora serrata, and the cornea and iris were removed, followed by
the removal of the lens and vitreous. The open eye-cup,
consisting of the intact retina, retinal pigment epithelium and
sclera, was cut into quadrants to allow it to lie flat, as a whole
mount preparation, with the integrity of the retinal circuitry
maintained and attached to the retinal pigment epithelium.
Perfusion and recording chamber
The retinal whole mount, ganglion cell layer side up, was
transferred to a blacked-out interface recording chamber.
The retina was held partially submerged and superfused with
oxygenated Krebs medium containing the following (mM):
NaCl 124, KCl 2, KH2PO4 1.25, MgSO4 1, CaCl2 2,
NaHCO3 26 and glucose 10, at 0.4 ml/min and 36 ± 0.2 °C.
The whole mount was left to recover for approximately
60 min prior to experimentation.
Response acquisition and recording electrode
Transretinal electroretinogram (ERG) and RGC field excitato-
ry post-synaptic potential (fEPSP) recordings were made via
Krebs medium-filled extracellular recording electrodes (2–
8 MΩ), pulled from borosilicate capillaries (1.2 × 0.69 mm,
Clark Electromedical Instruments). Responses were recorded
with an Axoprobe-1A amplifier (Axon Instruments), digitised
(5 kHz) via a CED1401 interface and stored on a computer
with Spike2 software (Cambridge Electronic Design Ltd.,
Cambridge, UK). Mains-related noise (50 Hz) was eliminated
with a Humbug noise reduction system (Quest Scientific).
To obtain transretinal ERG responses, the recording elec-
trode was manually lowered onto the surface of the retinal
whole mount, without breaking into the retinal layers. For
RGC fEPSP acquisition, a MS314 electronic micromanipula-
tor (Marzhauser-Wetzler) was used to further lower the elec-
trode vertically, from the surface of the whole mount in 5–
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10 μm steps, at a rate of 1 μm/step, every 10–15 s until break-
through to the ganglion cell layer, where recordings were ob-
tained. Figure 1 illustrates the positions of the recording elec-
trodes for acquisition of ERG and fEPSP responses.
Visual stimulation and characterisation of responses
The retinal whole mount was stimulated with a full-field, green
light-emitting diode (LED; λ = 562 nm) via a fibre-optic light
guide set 2 cm above the preparation. ERG responses were
stimulated with a 10-ms duration flash, repeated every 3 s.
RGC fEPSPs were stimulated with a 1-s duration flash, repeated
every 3 s. For all experiments, the light stimulus was set to an
intensity at which sub-maximal responses were elicited, typical-
ly within the range of −1.47 to −0.96 log cd s/m2.
Upon stimulation, the transretinal ERG exhibited a charac-
teristic waveform, composed of the negative a-wave, a prom-
inent and large-amplitude positive b-wave and oscillatory po-
tentials superimposed on the leading edge of the b-wave, qual-
itatively similar to rodent rod ERGs obtained in vivo [24]. For
the RGC fEPSP experiments, the onset and termination of the
light stimulus produced negative RGC ON- and OFF-fEPSPs,
respectively, similar to those described previously [25, 26].
Pharmacological investigations
Pharmacological compounds were added into the bathing me-
dium, which continuously superfused the retinal preparation
through the course of each experiment. All ERG experiments
were carried out in either physiological, low Mg2+, or a phar-
macologically modified Krebs medium (hereafter referred to
as PMSTN) that was composed of the following (mM): NaCl
124, KCl 2, KH2PO4 1.25, CaCl2 2, NaHCO3 26, glucose 10,
NBQX0.01, picrotoxin 0.1, strychnine 0.005 and tetrodotoxin
0.0001. AMPA, GABAA/C and glycine receptors and sodium
channels were blocked with NBQX, picrotoxin, strychnine
and tetrodotoxin, respectively. The effect of P2X7R activation
on synaptic transmission at rod photoreceptor-ON bipolar cell
synapses was investigated under three different conditions: (1)
physiological Krebs medium, (2) low Mg2+ Krebs medium
and (3) PMSTN (as with the RGC experiments). Firstly, nor-
mal Krebs medium was used to explore the effect of P2X7R
activation on the ERG under physiological conditions.
PMSTN medium was used as it allowed comparison of the
effect of P2X7R activation on the ERG and the ON-RGC
fEPSP under similar conditions. Additionally, it also enabled
us to identify whether an upstream mechanism in the outer
retina could be influencing the effect further downstream at
the level of the retinal ganglion cells. The use of the lowMg2+
perfusate enabled further characterisation of the role of
P2X7Rs in the retina, as their activation is considered to be
enhanced in the absence of divalent cations. All RGC fEPSP
experiments were undertaken using the PMSTN medium, in
order prevent action potential firing and to isolate and reveal
the NMDA-mediated component of the RGC ON-fEPSPs.
Differences in protocols for investigating P2X7R function
in ERG and RGC fEPSP experiments are highlighted where
necessary. The P2X7R agonist, BzATP, was applied for
10 min. For the concentration-response investigation of
BzATP on RGC ON-fEPSPs, no more than two applications
of BzATP were used on one preparation, regardless of con-
centration. The same protocol was followed for the
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Fig. 1 Placement of recording electrodes for acquisition of transretinal
electroretinogram and retinal ganglion cell fEPSP responses. Schematic
illustrates retinal circuitry and the respective positions of the recording
electrode for the electrophysiological experiments. The retinal whole
mount was placed in the bath, ganglion cell layer side up. The full-field
light flash stimulus was placed above the slice, and the arrow shows the
direction in which the light travelled. Top trace, Typical transretinal
electroretinogram response recorded by lowering the electrode onto the
surface of the retinal whole mount, without breaking into the layers. The
response was repeatedly elicited by a single 10-ms duration flash (green
arrow), with a 3-s interval. Bottom trace, Retinal ganglion cell fEPSPs
were recorded by placing the electrode in the ganglion cell layer. The
green bar represents the duration of the stimulus (1 s), which was
repeated at 3-s intervals. Upon stimulus onset, an ON retinal ganglion
cell fEPSP was generated. Stimulus offset produced an OFF retinal
ganglion cell fEPSP. ONL outer nuclear layer, OPL outer plexiform
layer, INL inner nuclear layer, IPL inner plexiform layer, GCL ganglion
cell layer, M microglia, cBC cone bipolar cell, rBC rod bipolar cell, AII
AII amacrine cell
Purinergic Signalling
concentration-response investigation of adenosine on RGC
fEPSP responses.
To test the effect of BzATP in the presence of the P2X7R
antagonist A438079 on both ERG and RGC fEPSP responses,
BzATP (300 μM) was added to the PMSTN medium for
10 min, followed by a 30–40-min washout period. A438079
was then added to the medium and allowed to superfuse the
retina until a stable response was reached (∼20–30 min).
BzATP was then co-applied with the antagonist-containing me-
dium. In separate experiments, the effect of the P2X7R antago-
nists A804598 and AF27139 (both prepared in DMSO) on the
BzATP-mediated effect on RGC fEPSPs was tested using the
same protocol as for A438079. As a control, DMSO (0.1 %)
was added to the PMSTN medium in these experiments.
Digital filtering and analysis of ERG components
The ERG traces were analysed offline using Spike2 software
(Cambridge Electronic Design, UK). Waveforms were initially
low-pass-filtered (<250 Hz) to reduce contamination of the
signal by high-frequency noise. A secondary low-pass filter
(<15 Hz) was applied to isolate a smoothed ERG and eliminate
the oscillatory potentials. Figure 2 shows no overall distortion in
the power spectra or waveforms of the low-frequency ERG
components (a-wave and b-wave), following two orders of
low-pass filtering. The smoothed waveform ensured accurate
measurement of the a-wave slope and b-wave amplitude with-
out contamination from the oscillatory potentials.
The slope of the a-wave, which reflects photoreceptor ac-
tivity [27], was measured between the onset and peak of the a-
wave. The b-wave peak amplitude was measured from the
peak of the a-wave to half the recovery phase of the b-wave
and is known to reflect ON bipolar cell function [28]. Sweeps
were analysed by averaging these parameters over 60 s,
throughout the time course of the experiment. Drug effects
on both response components were measured by calculating
the mean ± SEM percentage change in the measured parame-
ters (slope or amplitude), relative to control values. The im-
plicit time of the b-wave, in particular, can provide a measure
of photoreceptor sensitivity, whereas possible contamination
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Fig. 2 Digital filtering of transretinal electroretinogram responses. a
Dark-adapted electroretinogram (ERG) power spectra (300 s averages)
under various filter settings. The ERG was low-pass-filtered (<250 Hz;
dashed traces), with the prominent a-wave and b-wave components
within the low to mid frequency range. Further low-pass filtering
(<15 Hz; dotted traces) eliminated the high-frequency component
(oscillatory potentials). A high-pass filter (>60 Hz; solid trace) was
applied after the first filter in order to isolate the high-frequency
oscillatory potentials, which exhibited a peak frequency of
approximately 100 Hz. b Waveform averages illustrate the effect of the
filter settings on the shape of the ERG. Application of two orders of low-
pass filter did not distort the waveform keeping the a-wave and b-wave
intact. Application of the high-pass filter eliminated the a-wave and b-
wave isolating the oscillatory potentials for further analysis. Arrows
represent onset of flash stimulus (10 ms)
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of the a-wave by the onset of the b-wave must also be consid-
ered during analysis of the kinetics of these ERG components
[29]. The latencies were calculated from stimulus onset to the
peak amplitudes of the a-wave or b-wave, and values are
shown as mean ± SEM implicit time.
Oscillatory potentials were analysed in the frequency do-
main. These high-frequency wavelets are believed to reflect
inner retinal network function, particularly the activity of
amacrine and ganglion cells [30]. A secondary high-pass filter
(>60 Hz) was applied to isolate the oscillatory potentials from
the first filtered waveform, as shown in Fig. 2. The oscillatory
potentials exhibited a peak frequency of ∼90–110 Hz, which
is comparable to that of dark-adapted mouse ERGs in vivo
[31]. A fast Fourier transform was used to derive the power
spectrum of the oscillatory potentials, from stimulus onset to
the half-width of the b-wave recovery phase (∼240 ms). To
analyse drug effects, average spectra were generated 120 s
before, during and after drug application, and the mean
± SEM percentage change in peak power was compared with
control values.
Analysis of RGC ON-fEPSPs
RGC ON-fEPSP traces were also analysed offline using
Spike2 software (Cambridge Electronic Design, UK).
Responses were visualised as 3-s ‘sweeps’ and were analysed
by measuring the average amplitude of the ON-fEPSPs over
60 s, throughout the time course of the experiment. The effect
of pharmacological agents on the ON responses was measured
by calculating the mean ± SEM percentage change in fEPSP
amplitude, compared with control values.
Statistical analysis
Data were imported from Spike2 to Excel (Microsoft, USA)
for analysis and generating graphs. Statistical testing was car-
ried out using GraphPad Prism (v.6 for Windows, CA, USA).
For comparisons between baseline and drug effect on the re-
sponses, statistical significance was established using the
Wilcoxon matched pairs test. Comparisons between treatment
groups were carried out using the Mann-Whitney test. For all
tests, statistical significance was observed if P < 0.05.
Results
Suppression of the retinal ganglion cell ON-fEPSP
by BzATP and reduction of the effect by the selective
and competitive P2X7 receptor antagonists A438079,
A804598 and AF27139
TheeffectofP2X7RactivationonsynapticresponsesofRGCwas
investigated. All experiments were carried out in PMSTN
medium.As shown inFig. 3,BzATPwas applied to the perfusate
for10min,and theagonist-inducedmodulationof theON-fEPSP
was comparedacross concentrations ranging from10 to300μM.
There was no significant effect on the ON-fEPSP with low mi-
cromolar concentrations of BzATP. However, a concentration-
related reduction in theON-fEPSPpeakamplitudewasmeasured
at higher micromolar concentrations. BzATP at 300 μM, the
highest concentration tested, elicited a significant reduction in
the ON-fEPSP to 78.1 ± 3 % of control (P < 0.05, n = 21)
(Fig. 3a, b). BzATP elicited its effect within approximately 2–
3 min of reaching the retina and was sustained throughout the
duration of application (Fig. 3b(ii)). This effect was partially re-
coverable onwashout to 92.4 ± 2% of control (P < 0.05).
The effect of BzATP on the ON-fEPSP was assessed in the
presence of the selective, competitive P2X7R antagonists
A438079, A804598 or AF27139. Compared to the more clas-
sically used P2X7R antagonists, A438079 and A804598 are
generally considered amongst the most potent suppressors of
mouse P2X7R function, of those commercially available [32,
33]. AF27139 (Lundbeck, DK) is not yet commercially avail-
able, and A804598 has not been widely tested, but both have
shown to potently block P2X7R-mediated cytokine release in
cell culture preparations across species [33]. The less novel
A438079 was chosen for this study as it has demonstrated
potent suppression of P2X7R function in models of chronic
pain, microglial neuroinflammation and neurodegenerative
disorders in the spinal cord and brain [34–38]. The use of
A438079 in ex vivo retinal whole mount preparations has
not previously been reported, although the compound has
proven potent in suppressing swelling-induced damage to iso-
lated retinal ganglion cells [9].
Experiments were separate for each antagonist and
were carried out in PMSTN medium. The effect of each
antagonist on the BzATP-induced changes in the ON-
fEPSP was directly compared to the preceding applica-
tion of BzATP in the absence of the antagonist.
A438079 (10 μM), A804598 (30 μM) and AF27139
(30 μM) all partially attenuated the BzATP-mediated
reduction of the ON-fEPSP to 68.7 ± 2 %, 55.1 ± 11 %
and 75.2 ± 7 % of control, when compared to the max-
imum effect of BzATP (P < 0.05 for all) (Fig. 3c).
To explore whether the release of endogenous ATP acting on
P2X7Rs during visual stimulation affects ON-centre retinal gan-
glion cell activity, the effects of A438079, A804598 and
AF27139, when applied alone, were investigated (Fig. 3d).
The ON-fEPSP was reduced in the presence of A804598 to
85.0 ± 15%of control (P < 0.05, n = 7) but was not significantly
affected by A438079 or AF27139 at the concentrations tested.
Adenosine potentiates the retinal ganglion cell ON-fEPSP
Extracellular ATP is rapidly degraded into its constituent
adenosine by ectonucleotidases. It has previously been
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suggested that the actions of BzATP in the hippocampus
are due to the effect of its breakdown product Bz-
adenosine through the subsequent activation of A1 re-
ceptors [39]. Adenosine receptors are known to be
expressed in the retina. Therefore, it was investigated
whether the effect of BzATP on the RGC fEPSPs was
mediated by the activation of adenosine receptors.
The ON-fEPSP was significantly potentiated by aden-
osine, exhibiting a dose-related effect. For the highest
concentration tested (300 μM), maximum potentiation
was achieved within 3–5 min of adenosine exposure,
to 109.5 ± 2 % of control (P < 0.05, n = 8) (Fig. 4). The
effect on the ON-fEPSP peak amplitude was not
sustained but decayed prior to washout. A transient re-
duction in the ON-fEPSP was also observed before re-
covering fully, to 99.8 ± 2 % of control approximately
10 min later (P > 0.05), which is illustrated by the rep-
resentative traces (Fig. 4c). Vehicle application had no
significant effect on the ON-fEPSP (Fig. 4). These re-
sults suggest that the differential effects of BzATP and
adenosine on the ON-fEPSP are due to the activation of
different purinergic receptors.
P2X7R activation modulates rod photoreceptor-ON
bipolar cell synaptic transmission
The effect of P2X7R activation on synaptic transmission at rod
photoreceptor-ON bipolar cell synapses was investigated un-
der three different conditions. Dark-adapted retinal whole
mounts were used to record visually evoked ERG responses.
In physiological Krebs medium, a 10-min application of
BzATP induced a marked potentiation of the a-wave slope to
149.0 ± 14 % of control (P < 0.05, n = 13) (Fig. 5a(i)). The
BzATP-mediated changes in the a-wave were relatively rapid
in onset, reaching a sustained maximum effect within approx-
imately 5–6 min after the start of drug application. Following
washout of BzATP, the a-wave slope recovered to 108.2 ± 3%
of control (P > 0.05). BzATP also significantly increased the
implicit time of the a-wave maximum amplitude compared to
pre-treatment control (P < 0.05) (Fig. 5a(i)).
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Fig. 3 The effect of BzATP on the light-evoked ON-fEPSP. Responses
are pharmacologically isolated, NMDAR-mediated. BzATP was applied
(10 min) at concentrations of 10 (n = 2), 30 (n = 6), 100 (n = 6) and
300 μM (n = 21). Values are mean ± SEM percentage of pre-treatment
control fEPSP peak amplitude. a BzATP elicited a concentration-related
reduction of the ON-fEPSP. Washout of BzATP (300 μM) induced
recovery of the ON-fEPSP. b Time course plot shows the effect of
BzATP (300 μM) on the ON-fEPSP. Plotted values are mean ± SEM
percentage change in fEPSP peak amplitude, relative to pre-treatment
control. Representative traces (120 s averages) illustrate the effect of
BzATP (300 μM) on the ON-fEPSP. a Control, b BzATP (300 μM), c
wash. Scale bars = 400 ms, 20 μV. c Actions of selective P2X7R
antagonists on the BzATP-induced suppression of the ON-fEPSP. The
selective P2X7R antagonists, A438079 (n = 6), A804598 (n = 7) or
AF27139 (n = 6), significantly attenuated the BzATP (300 μM)-
mediated reduction of the ON-fEPSP. All three compounds exhibited
similar potency in blocking P2X7R function at the concentrations
tested. Note that in the presence of all antagonists, a large residual
effect on the ON-fEPSP persisted with BzATP application. d Direct
actions of selective P2X7R antagonists on the NMDAR-mediated ON-
fEPSP. The ON-fEPSP was significantly reduced in the presence of
A804598 (n = 7) but not by A438079 (n = 6) or AF27139 (n = 6) at the
concentrations tested. ns not significant; *P < 0.05, compared to control
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A concomitant reduction of the ERG b-wave ampli-
tude to 80.6 ± 4 % of control (P < 0.05, n = 13) was also
measured in the presence of BzATP (Fig. 5a(ii)). The
changes in the b-wave within 1–2 min of application
appeared to reach maximum reduction in amplitude im-
mediately prior to washout. Considering the direct out-
put of the photoreceptors onto the ON bipolar cells
along the vertical pathway, it would be expected that a
potentiation in the a-wave slope would lead to a subse-
quent increase in the b-wave amplitude. However, this
does not seem to be the case here, and is consistent
with the in vivo findings of the effect of BzATP on
the rat ERG [13]. The b-wave amplitude recovered to
baseline within approximately 10 min following wash-
out of BzATP (97.3 ± 3 % of control, P > 0.05). BzATP
application also induced a potentiation in the implicit
time of the b-wave (Fig. 5a(ii)). The differing effect of
BzATP on the kinetics of the a-wave and b-wave, as
has been previously demonstrated in vivo [13], suggests
that there are independent photoreceptor and post-
photoreceptor sites of action stimulated by the P2X7R
agonist.
The effect of BzATP-mediated activation of P2X7Rs is
considerably enhanced in the absence of extracellular divalent
cations, particularly magnesium ions (Mg2+) [16, 40]. To fur-
ther characterise the BzATP-mediated effect on the ERG
response components, the P2X7R agonist was applied in nor-
mal physiological medium that did not contain magnesium
ions. Under these conditions, BzATP induced a reduction in
the a-wave slope to 90.7 ± 3 % of control (P < 0.05, n = 6),
which was typically recoverable 5 min post-wash to 97.2
± 3 % of control (P > 0.05) (Fig. 5b(i)). Furthermore, BzATP
increased the implicit time of the a-wave maximum amplitude
(Fig. 5b(i)). The BzATP-mediated reduction in the a-wave
slope was contrary to that seen in the presence of extracellular
magnesium, suggesting that the effect of P2X7R activation is
reversed under these conditions.
In the absence of extracellular magnesium, BzATP sig-
nificantly reduced the b-wave amplitude to 89.5 ± 1 % of
control (P < 0.05, n = 6) (Fig. 5b(ii)). The temporal profile
of the b-wave amplitude was comparable to that of the a-
wave slope during the early phase of BzATP application,
where an exponential reduction in both components was
apparent. However, the differing recovery periods of the a-
and b-waves strongly support the notion that BzATP elic-
ited independent effects on photoreceptor and post-
photoreceptor components. Additionally, BzATP did not
elicit a significant effect on the implicit time of the b-wave
maximum amplitude (Fig. 5b(ii)). The suppressive effect
of BzATP on the b-wave amplitude in the presence and
absence of extracellular magnesium was similar in magni-
tude. The differences in the changes to the b-wave
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Fig. 4 The effect of adenosine on the NMDAR-mediated RGC ON-
fEPSP. Adenosine (ADO) was applied (10 min) at concentrations of
100 and 300 μM. n = 8 for both concentrations tested. a Values are
mean ± SEM percentage of pre-treatment control fEPSP peak
amplitude, taken ∼5–7 min after the start of adenosine application. The
ON-fEPSPwas reversibly and significantly potentiated by adenosine, in a
concentration-related manner. Vehicle application elicited no effect on the
ON-fEPSP. ns not significant; *P < 0.05, compared to control. b Time
course plot shows the effect of adenosine (300 μM; green) and vehicle
(yellow) on the ON-fEPSP. Plotted values are mean ± SEM percentage
change in fEPSP peak amplitude relative to pre-treatment control. c
Representative traces (120 s averages) illustrate the effect of adenosine
(300 μM) on the ON-fEPSPs
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amplitude during the post-wash phase under both condi-
tions imply that magnesium was required for full recovery
following BzATP application.
In separate experiments, the effects of BzATP on the ERG
a-wave and b-wave components were investigated in the pres-
ence of the antagonists NBQX, picrotoxin, strychnine and
tetrodotoxin and the absence of magnesium ions (PMSTN
medium). As shown in Fig. 5c(i), there was a significant re-
duction in the a-wave slope to 70.1 ± 8 % of pre-treatment
control after 5 min (P < 0.05, n = 7), with partial recovery fol-
lowing washout (76.3 ± 9 % of control, P < 0.05). The a-wave
was also significantly delayed in the presence of BzATP, re-
covering on washout (Fig. 5c(i)). Furthermore, there was a
significant difference in the BzATP-mediated effect on the a-
wave slope compared to that observed in the low magnesium
solution (P < 0.05).
The effect of BzATP on the b-wave amplitude, in the
PMSTN bathing medium, followed a similar temporal profile
to that of the a-wave slope, with a significant reduction to 66.6
± 10 % of control (P < 0.05, n = 7) (Fig. 5c(ii)) with little re-
covery following washout of BzATP. The b-wave implicit
time was also significantly increased with BzATP
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Fig. 5 The effect of BzATP on the dark-adapted ERG when recorded
under different conditions. Time course plots show the effect of BzATP
(300 μM; 10 min) on the a-wave slope and b-wave amplitude (bars).
Values are mean ± SEM percentage change and insets show mean
± SEM implicit time values. For all, ns not significant; *P < 0.05,
compared to pre-treatment control. a In physiological Krebs medium
(n = 13), BzATP induced a sustained potentiation of the a-wave slope
(i), which reached maximal effect within approximately 5 min of
application. BzATP concomitantly reduced the b-wave amplitude (ii)
over the course of application, an effect which was recoverable
following washout. b In the absence of extracellular magnesium ions
(n = 6), BzATP reduced the a-wave slope (i) and also caused a reduction
in the b-wave amplitude (ii) over the course of application, an effect
which was not fully recoverable following washout. c In the absence of
extracellular magnesium ions, and in the presence of NBQX, picrotoxin,
strychnine and TTX (n = 7), BzATP reduced the a-wave slope (i). The b-
wave amplitude was markedly suppressed (ii) and was not fully
recoverable following washout. Note the relatively similar effect of
BzATP on the b-wave, compared to that shown in b(ii). Representative
traces (a(iii), b(iii), c(iii)) illustrate the effect of BzATP on the ERG under
the respective conditions. Scale bars = 100 ms, 20 μV
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(Fig. 5c(ii)). Under these conditions, BzATP induced effects
on the b-wave amplitude (P > 0.05) which were comparable to
those seen in the absence of magnesium alone.
BzATP-induced modulation of the ERG a-wave
and b-wave was reduced by the selective P2X7R
antagonist A438079
In order to further delineate P2X7R involvement, the effect of
BzATP on the ERG components was assessed in the presence
of the selective, competitive P2X7R antagonist, A438079
(10 μM). The effect of A438079 on the BzATP-induced
changes in the a- and b-waves was directly compared to the
preceding application of BzATP in the same experiment.
When tested in physiological Krebs medium, A438079 sig-
nificantly reduced the potentiating effect of BzATP on the a-
wave slope to 57.3 ± 18 % of the effect of BzATP when ap-
plied alone (P < 0.05, n = 6) (Fig. 6a(i)). Similarly, the BzATP-
mediated suppression of the b-wave was markedly reduced in
the presence of the antagonist to 41.0 ± 30 % of control
(P < 0.05, n = 6) (Fig. 6a(ii)). Next, the effect of the P2X7R
antagonist on the action of BzATP was tested in PMSTN
medium. As shown in Fig. 7b(i), A438079 abolished the
BzATP-mediated reduction of the a-wave slope to 4 ± 16 %
of the effect of BzATP when applied alone (P < 0.05, n = 7).
Furthermore, A438079 reduced the effect of BzATP on the b-
wave amplitude to 58.3 ± 16 % of control (maximum BzATP
effect; P < 0.05) (Fig. 6b(ii)). Thus, the A438079-mediated
attenuation in the effect of BzATP on these components of
the ERG confirms the involvement of P2X7R activation.
The effect of direct application of the P2X7 receptor
antagonist A438079 on the dark-adapted
electroretinogram a-wave and b-wave components
To explore whether the release of endogenous ATP act-
ing on P2X7Rs during visual stimulation affects outer
retinal processing, the effect of A438079 on the ERG
when applied alone was investigated. In physiological
Krebs medium, A438079 (10 μM) alone did not induce
an effect on the a-wave (108.9 ± 10 % of control,
P > 0.05, n = 9) (Fig. 7a(i)). Similarly, the b-wave also
remained unaffected by the application of the antagonist
(93.3 ± 22 %, P > 0.05, n = 9) (Fig. 7a(ii)). Conversely, in
the pharmacologically modified perfusion medium, the
a-wave slope was significantly potentiated in the pres-
ence of A438079 (10 μM) alone, to 125.7 ± 12 % of
pre-treatment control (P < 0.05, n = 10). A438079 also
markedly reduced the b-wave amplitude to 79.1 ± 15 %
of control (P < 0.05, n = 10). The implicit times for both
a- and b-waves were increased in the presence of the
antagonist. These results suggest that P2X7R activation
may modulate retinal function under baseline conditions
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Fig. 6 Actions of the selective P2X7R antagonist A438079 on the
BzATP-mediated effects on the ERG components. Values are mean
± SEM percentage of control (max. BzATP effect, i.e. 100 %). a In
physiological Krebs medium (n = 6), the BzATP-mediated effects on the
a-wave slope (i) and b-wave amplitude (ii) were markedly reduced in the
presence of A438079 (10 μM) compared to control. b In the absence of
extracellular magnesium ions, and in the presence of NBQX, picrotoxin,
strychnine and TTX (n = 7), A438079 almost completely suppressed the
BzATP-mediated potentiation of the ERG a-wave compared to control. b
A438079-induced attenuation of the BzATP-mediated reduction in the b-
wave was also observed. *P < 0.05, compared to pre-treatment control
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but that this depends on the particular ionic conditions
of the microenvironment.
ERG oscillatory potentials are suppressed by P2X7R
activation
The effect of P2X7R activation on the ERG oscillatory poten-
tials was also explored, using physiological Krebs medium.
The high-frequency oscillatory potentials were digitally ex-
tracted from the raw ERG waveform (see Fig. 2). Changes
in the peak power output of the oscillatory potentials were
assessed with their frequency spectra before, during and after
application of the pharmacological compound. As seen with
the a-wave and b-wave components recorded in physiological
Krebs medium, A438079 alone had no significant effect on
the peak power of the oscillatory potentials (124.6 ± 25 % of
control, P > 0.05, n = 6).
BzATP significantly reduced the peak power to 58.8 ± 8 %
of control (P < 0.05, n = 13) (Fig. 8a, b). Following washout of
BzATP, the peak power of the oscillatory potentials recovered
to 97.9 ± 10 % of control (P > 0.05). Next, the effect of
A438079 was tested on the BzATP-induced suppression of
the oscillatory potentials. A438079 significantly reduced the
effect of BzATP on the oscillatory potential peak power to
68.2 ± 8 % of control (P < 0.05, n = 6) (Fig. 8c). These results
suggest that BzATP considerably suppressed the activity of
inner retinal networks, and further imply that P2X7R modula-
tion in the inner retina is at least partially independent of that
in the outer retina.
Discussion
P2X7Rs modulate the ON pathway in the outer and inner
retina
The present study has demonstrated that neuronal function in
both the outer and inner retina of the mouse under dark-
adapted conditions is considerably altered by P2X7R activa-
tion. An overview of the key findings are summarised in
Table 1. Furthermore, P2X7R modulation of visual responses
appears to occur through independent mechanisms, at differ-
ent levels of the rod pathway. These findings are not unex-
pected as P2X7Rs are expressed on photoreceptors; horizon-
tal, amacrine and retinal ganglion cells; and on non-neuronal
cells including microglia, retinal pigment epithelial cells and
vascular endothelial cells within the retina. As of yet, P2X7Rs
have not been localised to bipolar cells.
Modulation of outer retinal function
P2X7R-mediated alterations to synaptic transmission from rod
photoreceptors to rod-ON bipolar cells were assessed using
the dark-adapted ERG. Under physiological conditions,
P2X7R activation by its agonist, BzATP, potentiated the a-
wave, with a concomitant reduction in the b-wave. This find-
ing is consistent with previous work in the rat in vivo [13].
BzATP also delayed the time to peak of the a-wave, which
could indicate a reduction in photosensitivity of the rods [41].
However, in the study by Puthussery et al. [13], computational
extraction of the sensitivity parameter of the a-wave leading
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Fig. 7 The direct effect of the
selective P2X7R antagonist
A438079 on ERG components
under different physiological
conditions. Values are mean
± SEM percentage of pre-
treatment control; n = 10.
A438079 (10 μM) was
superfused for 20–30 min until
the response was stable. a In
physiological Krebs medium,
application of A438079 alone had
no overall effect on the a-wave (i)
or b-wave (ii). b In separate
experiments using the
pharmacologically modified
Krebs medium, A438079 induced
a marked potentiation in the a-
wave (i) compared to control
(P < 0.05). The b-wave (ii) was
significantly reduced in the
presence of A438079 (P < 0.05)
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edge indicated no change in photoreceptor sensitivity as a
result of P2X7R activation. Thus, the change in implicit time
of the a-wave in this investigation could instead be attributed
to a possible contamination of the BzATP-induced effect on
the b-wave.
The opposing effects of BzATP on the photoreceptor and
bipolar cell response components could be explained by a
mechanism associated with a change in the dark current of
the photoreceptors. Depolarisation of the photoreceptor
terminal induced by P2X7R activation would subsequently
potentiate the a-wave during photostimulation, due to a great-
er change in the photoreceptor dark current, as has been sug-
gested previously [13]. Concurrently, facilitation of the pho-
toreceptor dark current would increase the rate of glutamate
release in the dark, thus eliciting a smaller light-induced
depolarisation of the ON BCs. Stable calcium influx through
L-type channels is imperative for the sustained release of glu-
tamate from rod terminals in darkness [42]. A P2X7R-
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Fig. 8 The effect of BzATP on ERG oscillatory potentials. Experiments
were done in physiological Krebs medium. aMean ± SEM percentage of
control peak power; n = 7. BzATP (300 μM; 10 min) caused a reversible
and significant reduction in the peak power output of the oscillatory
potentials compared to control (P < 0.05), indicating modulation of
inner retinal function. b(i) Representative oscillatory potentials, before,
during and post-BzATP application. Black, control; blue, BzATP; grey,
wash. Under control conditions, the oscillatory potentials exhibited a
peak frequency ∼107 Hz, typical of dark-adapted ERG responses. In
the presence of BzATP, no overall shift in frequency was detected. b(ii)
Power Spectra (120 s) illustrate the BzATP-mediated suppression of the
oscillatory potentials and recovery on washout. Black control; blue,
BzATP; grey, wash. c A438079 (10 μM) significantly reduced the
BzATP-evoked suppression of the oscillatory potentials compared to
control. *P < 0.05, compared to pre-treatment control
Table 1 Summary of the effect of BzATP on the RGC ON-fEPSP and
ERG components in the absence and presence of P2X7R antagonists
under the physiological conditions tested. All values are expressed as
mean ± SEM. See text for n and P values. The effect of BzATP alone is
compared to pre-treatment control. The effect of BzATP in the presence
of an antagonist is compared to the maximum BzATP-mediated effect
Physiological Krebs Modified Krebs (PMSTN) Low Mg2+
RGC ON-fEPSP – BzATP: 78.1 ± 3 % –
BzATP + antagonist (% of max. BzATP effect)
A438079: 68.7 ± 2 %
A804598: 55.1 ± 11 %
AF27139: 75.2 ± 7 %
ERG a-wave BzATP: 149.0 ± 14 % BzATP: 70.1 ± 8 % BzATP: 90.7 ± 3 %
BzATP +A438079: 57.3 ± 18 % BzATP +A438079: 4 ± 16 % –
ERG b-wave BzATP: 80.6 ± 4 % BzATP: 66.6 ± 10 % BzATP: 89.5 ± 1 %
BzATP +A438079: 41.0 ± 30 % BzATP +A438079: 58.3 ± 16 % –
ERG OPs BzATP: 58.8 ± 8 % – –
BzATP +A438079: 68.2 ± 8 %
OPs oscillatory potentials
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dependent rise in intracellular calcium has previously shown
to directly stimulate vesicular glutamate release from hippo-
campal and cortical presynaptic terminals [20–22]. The pres-
ent findings suggest that P2X7R activation may modulate
ERG responses through a similar calcium-dependent mecha-
nism, although direct P2X7R modulation of ribbon synapses
has not yet been shown.
P2X7R activity is altered and most likely enhanced in the
absence of extracellular magnesium [16, 40]. In the present
study, removal of magnesium ions from the perfusate reversed
the effect of P2X7R activation on the a-wave, instead inducing
a marked reduction in the photoreceptor response. This sup-
ports the concept of a bi-directional function of P2X receptors
in modulating synaptic activity dependent upon the physio-
logical context, as has been consistently evident in central
synapses, particularly in the hippocampus [43]. Without ex-
tracellular magnesium, the b-wave was suppressed by BzATP,
to a similar magnitude, when compared to the effect in the
presence of the divalent cation. Contrary to the observed effect
in physiological perfusate, the BzATP-mediated suppression
of the b-wave was not reversible in the absence of magnesium.
The differential temporal profiles of the effect of BzATP on
the a- and b-waves highlight independent sites of modulation
by P2X7Rs in both the inner and outer retina.
In the present study, the suppressive effect of P2X7R acti-
vation on the photoreceptor response was enhanced in the
presence of blockers of GABAA/C, glycine and AMPA/KA
receptors and of voltage-gated sodium channels. It has previ-
ously been suggested that P2X7R-associated modulation of
the mouse ERG may be due to alterations in horizontal and
amacrine cell feedback [7]. However, the underlying mecha-
nism of modulation of the photoreceptor response may not be
associated with the release of inhibitory inputs to the rod ter-
minals under dark-adapted conditions [44]. Indeed, the study
by Vessey and Fletcher [7] found that the ERG a-wave was
unaltered, whereas the b-wave was markedly potentiated in a
P2X7R-knockout mouse model. In the present investigation,
there was no overall difference in the BzATP-induced reduc-
tion in the b-wave, between responses recorded in the absence
of magnesium alone, and with the addition of pharmacologi-
cal blockers of inhibitory neurotransmission. This indicates
that P2X7R-mediated modulation of the ON BCs is not due
to an effect on inhibitory feedback at the ON BC terminal in
the inner retina. Since BCs do not themselves express
P2X7Rs, these results could reflect a possible modulation of
both ERG components by non-neuronal cells during P2X7R
stimulation.
The involvement of P2X7R-mediated modulation of the a-
wave was confirmed with the selective antagonist A438079,
whichmarkedly suppressed and abolished the effect of P2X7R
activation on the photoreceptor response, when tested in phys-
iological Krebs and the pharmacologically modified medium,
respectively. Similarly, A438079 partially blocked P2X7R
modulation of the ON bipolar cell response under both condi-
tions tested. The presence of a residual effect of BzATP even
with the addition of a selective P2X7R antagonist supports the
notion that a consistent or secondary stress-related release of
large amounts of endogenous ATP, possibly by non-neuronal
cells, could act to influence retinal synaptic signalling.
To explore whether P2X7Rs have a physiological role in
outer retinal function upon visual stimulation, we investigated
the effects of A438079 alone on the ERG components. When
recorded in the physiological Krebs medium, blockade of
P2X7Rs had no overall effect on the a-wave or b-wave. This
contradicts previous findings whereby the b-wave was signif-
icantly potentiated in a P2X7R knockout model [7]. However,
both ERG components were markedly suppressed when the
antagonist was applied in the modified perfusion medium. A
sensitised or stressed cellular microenvironment can initiate
acute changes to glutamate and ATP homeostasis and signal-
ling. Such deviations from the physiological norm may in-
crease the likelihood of ATP release in the outer retina, at a
sufficient concentration to activate P2X7Rs and subsequently
affect the processing of the visual signal.
These results strongly suggest a direct role for P2X7Rs in
photoreceptors in modulating outer retinal processing and are
supported by studies that have shown P2X7R immunoreactiv-
ity at ribbon synapses within the rod spherule, in the rodent
retina [7, 12, 13]. However, P2X7R modulation of photore-
ceptor function through alternative mechanisms cannot be
ruled out. The P2X7R expression profile in the healthy rabbit
[9] and human retina [36, 45] has shown no evidence of im-
munoreactivity in photoreceptors and may instead support the
concept that P2X7Rs may modulate photoreceptor function
through its expression in retinal pigment epithelial cells in
the absence of pathology. Indeed, RPE cells are sources of
ATP, which can be released in response to hyperosmotic stress
[46], through various mechanisms including ATP-triggered
secondary ATP release, CFTR-dependent ATP efflux as well
as vesicular ATP secretion, as demonstrated in human retinal
cells [47]. This autostimulatory ATP release may be driven
through P2X7R-associated panx-1 hemichannels, as shown
in the bovine retina [48]. Furthermore, RPE cells have dem-
onstrated the presence of ectonucleotidases [46], which may
rapidly degrade ATP into its constituents, in order to activate
other P2 and adenosine receptors in cells of the outer retina,
and therefore influence synaptic signalling through alternative
mechanisms.
Modulation of inner retinal function
The present study has demonstrated that P2X7R activation
distinctly influences the activity of inner retinal networks, as
shown by the changes observed in the ERG oscillatory poten-
tials. A clear effect of P2X7R activation on the ON pathway
was apparent, as BzATP suppressed the ON-fEPSP in a
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concentration-related manner. The involvement of P2X7Rs in
modulating the ON-fEPSP was supported by the partially at-
tenuated effect of BzATP in the presence of the selective
P2X7R antagonists A438079, A804598 or AF27139. With
each antagonist, a residual effect of BzATP on the ON-
fEPSP remained, which could be explained by a lack of po-
tency of these compounds for blocking P2X7R-mediated ef-
fects in the inner retinal layers.
As with the outer retina, the lack of potency of these com-
pounds in suppressing the BzATP-mediated reduction in ON-
centre RGC responses could be due to the stimulated release
of endogenous ATP within the inner retinal layers. ATP is
present in high concentrations within all metabolically active
cells and so all can function as sources of ATP, which may
then act to compete with the antagonist at the receptor.
Alternatively, P2X7Rs are known to drive ATP release which
can then act cell-autonomously. Indeed, P2X7R-mediated,
non-vesicular release of ATP has been demonstrated in retinal
ganglion cells [9]. P2X7Rs are expressed on amacrine, gangli-
on and microglial cells in the inner mouse retina and are all
therefore potential sources of ATP-mediated ATP release.
In the absence of pathology or inflammation, the expression
of functional P2X7Rs has only been demonstrated in Müller
cells of the human retina but not in those of other mammalian
species [49]. However, it has been shown in the rat retina that
light-evoked ATP release from ganglion cells increases Müller
cell Ca2+ transients through activation of glial P2YRs. This in
turn mediates the release of glial ATP, which is rapidly hydro-
lysed into adenosine, in turn hyperpolarising ganglion cells
through the activation of A1 receptors [50]. It has been pro-
posed that the BzATP-mediated suppression of excitatory re-
sponses in the rodent hippocampus and brainstem was attribut-
ed to its breakdown product Bz-adenosine and subsequent ac-
tivation of adenosine receptors [39, 51]. Adenosine facilitated
the ON-fEPSP for a short period before the effect diminished,
leading to a temporary suppression of the ON-fEPSP before
recovery on washout. This may be due to a number of factors,
which include receptor desensitisation or clearance of adeno-
sine from the extracellular environment via nucleoside trans-
porters expressed in Müller cells. In the present study, the pos-
sible contribution of A1 receptors to the BzATP-mediated re-
duction of the ON-fEPSP was ruled out. Adenosine produced a
dose-related potentiation in the ON-fEPSP, an effect which
followed a differential temporal profile to that seen for the effect
of BzATP. This suggests that adenosine facilitates possibly
through A3 receptors, whereas P2X7Rs appear to reduce neu-
ronal activity within the ON pathway.
Although BzATP is a potent agonist of P2X7Rs, it is not
selective for the receptor and can bind to P2X1, P2X2 and
P2X3 receptors with similar potency [17], and therefore, the
possibility remains that these receptor subtypes may also be
activated in the presence of the agonist. P2X1R immunoreactiv-
ity has been localised to the inner retinal layers of the cat and
monkey retina [52], although evidence of its expression and
function in the mouse is uncertain. In the rodent, P2X3Rs have
been detected in the inner plexiform layer [53]. On activation,
both P2X1Rs and P2X3Rs rapidly desensitise [1], and thus their
kinetic profiles do not correlate with the BzATP-mediated ef-
fects observed in the present study. Selective expression of
P2X2Rs in starburst amacrine cells within the OFF vertical path-
way has been demonstrated in the mouse retina [54, 55].
Although P2X2Rs display slowly desensitising properties simi-
lar to P2X7Rs, it is uncertain whether they would directly affect
neuronal responses within the ON pathway.
Metabotropic P2Y receptors may also modulate visual re-
sponses in the retina as they have been suggested to play a role
in glial-neuronal cross-talk [48]. Indeed both functional and im-
munohistochemical expression of P2Y1Rs on Müller cells [11,
48, 56, 57] and P2Y4R on rod bipolar and amacrine cells [58]
have been demonstrated in the retina. Considering that ADP and
UTP are markedly more potent agonists at these receptors, re-
spectively [59], their direct contribution to the BzATP-mediated
effect on visual responses in the present study is unlikely.
However, it is important to note that the remarkable diversity
of purinergic receptors in such an intimate retinal microenviron-
ment opens the possibility of their contribution to the overall
glial-neuronal cross-talk in the processing of visual information,
through the secondary release of endogenous purinergic ligands.
The present findings are in accord with previous findings
[8, 10] on P2X7R function in the retina and extend these find-
ings to show that activation of these receptors can affect func-
tion at different sites in the retinal ON pathway. Thus, activa-
tion of these receptors under pathophysiological conditions by
high concentrations of ATP would likely affect function at all
stages of visual transmission in the retina.
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